Molecular-Driven Therapy in Advanced Thyroid Cancer.
Opinion Statement: With a growing understanding of the biologic drivers of different thyroid cancers, there is an ongoing revolution in the treatment of aggressive and advanced disease variants. This includes matching patients with specific point mutations or gene fusions to targeted therapies (e.g....
| Publicado en: | Current Treatment Options in Oncology Vol. 22; no. 3; pp. 1 - 15 |
|---|---|
| Autores principales: | , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Mar2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149470590&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 149470590 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15272729 3KHC jtl: Current Treatment Options in Oncology issn: 15272729 maglogo: N pubinfo: dt: Mar2021 vid: 22 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 149470590 149470590 NLM33569661 149470590 10.1007/s11864-021-00822-7 NLM33569661 149470590 ppf: 1 ppct: 14 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Molecular-Driven Therapy in Advanced Thyroid Cancer. aug: au: Miller, Kevin C. Chintakuntlawar, Ashish V. affil: Department of Medicine, Massachusetts General Hospital, Boston, MA, USA sug: subj: Drug Therapy Adverse Effects Drug Therapy Methods Thyroid Neoplasms Therapy Disease Susceptibility Thyroid Neoplasms Etiology Human Neoplasm Staging Neoplasm Grading Disease Management Treatment Outcomes Combined Modality Therapy Prognosis Genomics Methods Thyroid Neoplasms Diagnosis Thyroid Neoplasms Mortality Scales ab: Opinion Statement: With a growing understanding of the biologic drivers of different thyroid cancers, there is an ongoing revolution in the treatment of aggressive and advanced disease variants. This includes matching patients with specific point mutations or gene fusions to targeted therapies (e.g., selective RET inhibitors), delineating patients who are likely to respond to immune checkpoint inhibition (i.e., PD-L1-positive tumors) and even priming responses to traditional therapies such as radioactive iodine (via concomitant MAPK pathway inhibition). There is also a growing role for genomics in the prognostication of thyroid tumors to aid the adjudication of appropriate treatments. Taking stock of the current state of the field, recent successes should be celebrated, but there still remains a long road ahead to improve outcomes for patients, particularly for radioactive-iodine refractory differentiated thyroid cancer and anaplastic thyroid cancer. In this review, we summarize findings from recent clinical trials and highlight promising preclinical data supporting molecular-driven therapy in advanced thyroid cancer. Ultimately, enrollment in clinical trials remains paramount to the advancement of thyroid cancer care. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|